ACT Capital Management LLC Invests $768,000 in Kura Oncology, Inc. $KURA

ACT Capital Management LLC bought a new position in Kura Oncology, Inc. (NASDAQ:KURA) during the 4th quarter, HoldingsChannel.com reports. The fund bought 73,900 shares of the company’s stock, valued at approximately $768,000. Kura Oncology comprises approximately 0.6% of ACT Capital Management LLC’s holdings, making the stock its 29th biggest holding.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KURA. State Street Corp grew its position in Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC grew its position in Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock valued at $19,020,000 after purchasing an additional 965,256 shares in the last quarter. AQR Capital Management LLC grew its position in Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock valued at $31,816,000 after purchasing an additional 820,020 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its position in Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after purchasing an additional 738,761 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KURA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. UBS Group reiterated a “buy” rating and issued a $15.00 target price (down from $16.00) on shares of Kura Oncology in a research note on Friday, March 13th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.46.

Kura Oncology Price Performance

NASDAQ:KURA opened at $9.57 on Thursday. The stock has a market cap of $849.53 million, a P/E ratio of -2.86 and a beta of 0.36. Kura Oncology, Inc. has a one year low of $5.45 and a one year high of $12.49. The company has a fifty day moving average price of $9.37 and a 200 day moving average price of $9.26. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The firm had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Analysts anticipate that Kura Oncology, Inc. will post -3.47 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.